Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: A randomised phase 3 trial
The Lancet Oncology, 07/07/2011
Coiffier B et al.
– A regimen of bortezomib plus rituximab is feasible. The improvement in progression-free survival provided by this regimen versus rituximab alone was not as great as expected. The regimen might represent a useful addition to the armamentarium, particularly for some subgroups of patients.
Multicentre phase 3 trial, rituximab-naive or rituximab-sensitive patients aged 18 years or older with relapsed grade 1 or 2 follicular lymphoma were randomly assigned (1:1) to receive five 35-day cycles consisting of intravenous infusions of rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and on day 1 of cycles 2—5, either alone or with bortezomib 1·6 mg/m2, administered by intravenous injection on days 1, 8, 15, and 22 of all cycles
Between April 10, 2006, and Aug 12, 2008, 676 patients were randomised to receive rituximab (n=340) or bortezomib plus rituximab (n=336)
After median follow-up of 33·9 months (IQR 26·4—39·7), median PFS 11·0 months (95% CI 9·1—12·0) in rituximab group and 12·8 months (11·5—15·0) in bortezomib plus rituximab group (HR 0·82, 95% CI 0·68—0·99; p=0·039)
Magnitude of clinical benefit not as large as anticipated prespecified improvement of 33% in PFS
Patients in both groups received median of 5 treatment cycles (range 1—5); 245 of 339 (72%) and 237 of 334 (71%) patients in rituximab and bortezomib plus rituximab groups completed 5 cycles
Of patients who did not complete 5 cycles, most discontinued early because of disease progression (77 [23%] patients in rituximab group, and 56 [17%] patients in bortezomib plus rituximab group)
Rates of AE of grade 3 or higher (70 [21%] of 339 rituximab-treated patients vs 152 [46%] of 334 bortezomib plus rituximab treated patients), and serious AE (37 [11%] patients vs 59 [18%] patients) lower in rituximab group than in combination group
Most common AE of grade 3 or higher were neutropenia (15 [4%] patients in rituximab group and 37 [11%] patients in bortezomib plus rituximab group), infection (15 [4%] patients and 36 [11%] patients, respectively), diarrhea (no patients and 25 [7%] patients), herpes zoster (one [<1%] patient and 12 [4%] patients), nausea or vomiting (two [<1%] patients and 10 [3%] patients, respectively) and thrombocytopenia (2 [<1%] patients and 10 [3%] patients)
No individual serious AE reported by more than 3 patients in rituximab group; in bortezomib plus rituximab group, only pneumonia (7 patients [2%]) and pyrexia (6 patients [2%]) reported in more than 5 patients
In bortezomib plus rituximab group 57 (17%) of 334 patients had peripheral neuropathy (including sensory, motor, and sensorimotor neuropathy), including 9 (3%) with grade 3 or higher, compared with three (1%) of 339 patients in rituximab group (no events of grade ?3)
No patients in rituximab group but 3 (1%) patients in bortezomib plus rituximab group died of AE considered at least possibly related to treatment
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.